Ben-Chetrit, Nir http://orcid.org/0000-0003-1112-0537
Niu, Xiang
Swett, Ariel D. http://orcid.org/0000-0003-4279-5895
Sotelo, Jesus
Jiao, Maria S. http://orcid.org/0000-0002-6439-8906
Stewart, Caitlin M. http://orcid.org/0000-0002-5070-4810
Potenski, Catherine
Mielinis, Paulius
Roelli, Patrick
Stoeckius, Marlon http://orcid.org/0000-0002-5658-029X
Landau, Dan A. http://orcid.org/0000-0003-2346-9541
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | NIH Office of the Director (DP2-CA239065)
Vallee Foundation (VS-2020-31)
Leukemia and Lymphoma Society (1373-21)
Sontag Foundation (SFI 203261-02)
Fred L. Emerson Foundation (584001)
Article History
Received: 21 March 2022
Accepted: 29 September 2022
First Online: 2 January 2023
Competing interests
: M.S., P.M. and P.R. are current employees of 10x Genomics, Sweden. D.A.L. has served as a consultant for Abbvie, AstraZeneca and Illumina, and is on the Scientific Advisory Board or equity holder of Mission Bio, Pangea, Alethiomics and C2i Genomics. D.A.L. has also received previous research funding from BMS, 10x Genomics, Ultima Genomics and Illumina unrelated to the current manuscript. The other authors declare no competing interests.